AG˹ٷ

STOCK TITAN

[S-8] Assembly Biosciences, Inc Employee Benefit Plan Registration

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
S-8
Rhea-AI Filing Summary

Interface Inc. (TILE) � Form 144 filing

An affiliate intends to sell up to 79,497 common shares through Morgan Stanley Smith Barney on or after 6 Aug 2025. At the stated reference price, the shares are worth about $2.04 million, representing only 0.14 % of the 58.36 million shares outstanding.

The stock was obtained via multiple restricted-stock vestings between January 2024 and February 2025 under the company’s equity compensation plan. The filer reports no sales during the prior three months and certifies awareness of no undisclosed adverse information.

Given the small size and scheduled nature, the notice appears routine, but investors may view continued insider monetization as a modest sentiment headwind.

Interface Inc. (TILE) � Deposito del Modulo 144

Un affiliato intende vendere fino a 79.497 azioni ordinarie tramite Morgan Stanley Smith Barney a partire dal 6 agosto 2025. Al prezzo di riferimento indicato, le azioni valgono circa 2,04 milioni di dollari, rappresentando solo lo 0,14% delle 58,36 milioni di azioni in circolazione.

Le azioni sono state ottenute tramite più vesting di azioni vincolate tra gennaio 2024 e febbraio 2025, nell’ambito del piano di compensazione azionaria della società. Il dichiarante segnala nessuna vendita negli ultimi tre mesi e certifica di non essere a conoscenza di informazioni negative non divulgate.

Data la dimensione contenuta e la natura programmata, la comunicazione sembra di routine, ma gli investitori potrebbero interpretare la continua monetizzazione da parte degli insider come un leggero fattore negativo per il sentiment.

Interface Inc. (TILE) � Presentación del Formulario 144

Un afiliado planea vender hasta 79,497 acciones comunes a través de Morgan Stanley Smith Barney a partir del 6 de agosto de 2025. Al precio de referencia indicado, las acciones tienen un valor aproximado de 2,04 millones de dólares, representando solo el 0,14 % de las 58,36 millones de acciones en circulación.

Las acciones fueron adquiridas mediante múltiples adquisiciones de acciones restringidas entre enero de 2024 y febrero de 2025 bajo el plan de compensación accionaria de la compañía. El declarante informa no haber realizado ventas en los últimos tres meses y certifica que no tiene conocimiento de información adversa no divulgada.

Dado el tamaño reducido y la naturaleza programada, la notificación parece rutinaria, pero los inversores podrían ver la continua monetización interna como un leve factor negativo para el sentimiento.

Interface Inc. (TILE) � Form 144 제출

� 계열사가 2025� 8� 6� 이후 Morgan Stanley Smith Barney� 통해 최대 79,497 보통�� 매각� 예정입니�. 명시� 기준 가격으� 해당 주식 가치는 � 204� 달러� 달하�, 이는 전체 발행 주식 5,836� 주의 0.14%� 해당합니�.

� 주식들은 2024� 1월부� 2025� 2� 사이� 회사� 주식 보상 계획� 따라 여러 차례 제한 주식 권리 확정(vesting)� 통해 취득되었습니�. 제출자는 최근 3개월� 매도 내역� 없음� 보고하며, 공개되지 않은 불리� 정보가 없음� 확인합니�.

규모가 작고 예정� 거래라는 점에� 이번 공시� 일상적인 것으� 보이�, 투자자들은 내부자의 지속적� 주식 매각� 다소 부정적� 심리 요인으로 인식� � 있습니다.

Interface Inc. (TILE) � Dépôt du formulaire 144

Un affilié a l’intention de vendre jusqu’� 79 497 actions ordinaires via Morgan Stanley Smith Barney à partir du 6 août 2025. Au prix de référence indiqué, ces actions valent environ 2,04 millions de dollars, ce qui ne représente que 0,14 % des 58,36 millions d’actions en circulation.

Les actions ont été obtenues par plusieurs levées de restrictions d’actions entre janvier 2024 et février 2025 dans le cadre du plan de rémunération en actions de la société. Le déclarant rapporte aucune vente au cours des trois derniers mois et certifie ne pas avoir connaissance d’informations défavorables non divulguées.

Compte tenu de la faible quantité et du caractère programmé, l’avis semble être une formalité, mais les investisseurs pourraient considérer la monétisation continue par les initiés comme un léger vent contraire pour le sentiment.

Interface Inc. (TILE) � Form 144 Einreichung

Ein verbundenes Unternehmen beabsichtigt, bis zu 79.497 Stammaktien über Morgan Stanley Smith Barney ab dem 6. August 2025 zu verkaufen. Zum angegebenen Referenzpreis haben die Aktien einen Wert von etwa 2,04 Millionen US-Dollar und stellen lediglich 0,14 % der 58,36 Millionen ausstehenden Aktien dar.

Die Aktien wurden im Rahmen des Aktienvergütungsplans des Unternehmens durch mehrere Restricted-Stock-Vestings zwischen Januar 2024 und Februar 2025 erworben. Der Meldende gibt keine Verkäufe in den letzten drei Monaten an und bestätigt, keine nicht offengelegten negativen Informationen zu kennen.

Angesichts der geringen Größe und des geplanten Charakters erscheint die Meldung routinemäßig, jedoch könnten Anleger die fortgesetzte Monetarisierung durch Insider als leichten Gegenwind für die Stimmung werten.

Positive
  • Sale equals only 0.14 % of shares outstanding, limiting market impact and dilution.
  • No shares sold in the prior three months, indicating limited recent insider selling activity.
Negative
  • Insider plans to liquidate $2.04 million in stock, potentially viewed as reduced confidence.
  • Filing authorizes sales within the next 90 days, adding minor selling pressure risk.

Insights

TL;DR: Tiny insider sale (~0.14 % float) is routine and should not move TILE’s valuation.

The proposed $2 million sale is immaterial relative to daily trading volume and market cap. Shares stem from normal equity compensation vestings, with no prior 3-month disposals. Liquidity impact and dilution are negligible; therefore, I view the filing as neutral for the stock.

TL;DR: Rule 144 filing signals scheduled stock cash-out; governance risk low but insider sentiment bears monitoring.

Disposals via a broker suggest compliance with Rule 144 and possible 10b5-1 planning, reducing information-abuse concerns. Nonetheless, recurring insider sales can weigh on perception if cumulative volumes rise. Current transaction size is minor, keeping governance implications neutral.

Interface Inc. (TILE) � Deposito del Modulo 144

Un affiliato intende vendere fino a 79.497 azioni ordinarie tramite Morgan Stanley Smith Barney a partire dal 6 agosto 2025. Al prezzo di riferimento indicato, le azioni valgono circa 2,04 milioni di dollari, rappresentando solo lo 0,14% delle 58,36 milioni di azioni in circolazione.

Le azioni sono state ottenute tramite più vesting di azioni vincolate tra gennaio 2024 e febbraio 2025, nell’ambito del piano di compensazione azionaria della società. Il dichiarante segnala nessuna vendita negli ultimi tre mesi e certifica di non essere a conoscenza di informazioni negative non divulgate.

Data la dimensione contenuta e la natura programmata, la comunicazione sembra di routine, ma gli investitori potrebbero interpretare la continua monetizzazione da parte degli insider come un leggero fattore negativo per il sentiment.

Interface Inc. (TILE) � Presentación del Formulario 144

Un afiliado planea vender hasta 79,497 acciones comunes a través de Morgan Stanley Smith Barney a partir del 6 de agosto de 2025. Al precio de referencia indicado, las acciones tienen un valor aproximado de 2,04 millones de dólares, representando solo el 0,14 % de las 58,36 millones de acciones en circulación.

Las acciones fueron adquiridas mediante múltiples adquisiciones de acciones restringidas entre enero de 2024 y febrero de 2025 bajo el plan de compensación accionaria de la compañía. El declarante informa no haber realizado ventas en los últimos tres meses y certifica que no tiene conocimiento de información adversa no divulgada.

Dado el tamaño reducido y la naturaleza programada, la notificación parece rutinaria, pero los inversores podrían ver la continua monetización interna como un leve factor negativo para el sentimiento.

Interface Inc. (TILE) � Form 144 제출

� 계열사가 2025� 8� 6� 이후 Morgan Stanley Smith Barney� 통해 최대 79,497 보통�� 매각� 예정입니�. 명시� 기준 가격으� 해당 주식 가치는 � 204� 달러� 달하�, 이는 전체 발행 주식 5,836� 주의 0.14%� 해당합니�.

� 주식들은 2024� 1월부� 2025� 2� 사이� 회사� 주식 보상 계획� 따라 여러 차례 제한 주식 권리 확정(vesting)� 통해 취득되었습니�. 제출자는 최근 3개월� 매도 내역� 없음� 보고하며, 공개되지 않은 불리� 정보가 없음� 확인합니�.

규모가 작고 예정� 거래라는 점에� 이번 공시� 일상적인 것으� 보이�, 투자자들은 내부자의 지속적� 주식 매각� 다소 부정적� 심리 요인으로 인식� � 있습니다.

Interface Inc. (TILE) � Dépôt du formulaire 144

Un affilié a l’intention de vendre jusqu’� 79 497 actions ordinaires via Morgan Stanley Smith Barney à partir du 6 août 2025. Au prix de référence indiqué, ces actions valent environ 2,04 millions de dollars, ce qui ne représente que 0,14 % des 58,36 millions d’actions en circulation.

Les actions ont été obtenues par plusieurs levées de restrictions d’actions entre janvier 2024 et février 2025 dans le cadre du plan de rémunération en actions de la société. Le déclarant rapporte aucune vente au cours des trois derniers mois et certifie ne pas avoir connaissance d’informations défavorables non divulguées.

Compte tenu de la faible quantité et du caractère programmé, l’avis semble être une formalité, mais les investisseurs pourraient considérer la monétisation continue par les initiés comme un léger vent contraire pour le sentiment.

Interface Inc. (TILE) � Form 144 Einreichung

Ein verbundenes Unternehmen beabsichtigt, bis zu 79.497 Stammaktien über Morgan Stanley Smith Barney ab dem 6. August 2025 zu verkaufen. Zum angegebenen Referenzpreis haben die Aktien einen Wert von etwa 2,04 Millionen US-Dollar und stellen lediglich 0,14 % der 58,36 Millionen ausstehenden Aktien dar.

Die Aktien wurden im Rahmen des Aktienvergütungsplans des Unternehmens durch mehrere Restricted-Stock-Vestings zwischen Januar 2024 und Februar 2025 erworben. Der Meldende gibt keine Verkäufe in den letzten drei Monaten an und bestätigt, keine nicht offengelegten negativen Informationen zu kennen.

Angesichts der geringen Größe und des geplanten Charakters erscheint die Meldung routinemäßig, jedoch könnten Anleger die fortgesetzte Monetarisierung durch Insider als leichten Gegenwind für die Stimmung werten.

As filed with the Securities and Exchange Commission on August 6, 2025

 

Registration No. 333-

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933

Assembly Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware

20-8729264

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

Two Tower Place, 7th Floor
South San Francisco, California

94080

(Address of Principal Executive Offices)

(Zip Code)

Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan

Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan

(Full title of the plan)

Jason A. Okazaki

Chief Executive Officer and President

Assembly Biosciences, Inc.

Two Tower Place, 7th Floor
South San Francisco, California 94080

(Name and address of agent for service)

(833) 509-4583

(Telephone number, including area code, of agent for service)

Copies to:

P. Michelle Gasaway, Esq.

Skadden, Arps, Slate, Meagher & Flom LLP

300 South Grand Avenue, Suite 3400

Los Angeles, California 90071

(213) 687-5000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

 

 

 

 


 

EXPLANATORY NOTE

Pursuant to General Instruction E to Form S-8 under the Securities Act, this Registration Statement is being filed by Assembly Biosciences, Inc. (the “Company” or the “Registrant”) for the purpose of registering additional shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) under (1) the Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan (the “2018 Plan”) and (2) the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan (the “2018 ESPP”).

On April 23, 2024, the Company filed with the Securities and Exchange Commission (the “Commission”) a definitive proxy statement (the “Proxy Statement”) that included separate proposals to increase the number of shares reserved for issuance under the 2018 Plan by (1) 375,000 shares of Common Stock for general purposes and (2) 225,000 shares of Common Stock for issuance solely in connection with a supplemental retention program. This Registration Statement registers the 600,000 aggregate additional shares of Common Stock reserved for issuance under the 2018 Plan.

The Proxy Statement also included a proposal to increase the number of shares reserved for issuance under the 2018 ESPP by 60,500 shares of Common Stock for issuance. This Registration Statement registers the 60,500 additional shares of Common Stock reserved for issuance under the 2018 ESPP.

On February 9, 2024, we effectuated a 1-for-12 reverse stock split (the "Reverse Stock Split"), which also impacted the number of shares reserved for issuance under our equity plans. As a result of the Reverse Stock Split, as of February 9, 2024, the number of shares of Common Stock that were registered for issuance under the 2018 Plan was reduced from 10,600,000 shares to 833,333 shares, and the number of shares that were registered for issuance under the 2018 ESPP was reduced from 1,300,000 shares to 108,333 shares. Both plans were amended and restated in 2024, and additional shares for the two plans were registered pursuant to a Registration Statement on Form S-8 (Registration No. 333-281388) filed on August 8, 2024.

Prior Registration Statements

The 600,000 additional shares of Common Stock reserved for issuance under the 2018 Plan registered pursuant to this Registration Statement are of the same class of securities as the shares of Common Stock registered for issuance under the 2018 Plan pursuant to the following currently effective registration statements: (1) the Registration Statement on Form S-8 (Registration No. 333-226703) filed on August 8, 2018 (the “Original 2018 Plan Registration Statement”), (2) the Registration Statement on Form S-8 (Registration No. 333-233030) filed on August 5, 2019 (the “Second 2018 Plan Registration Statement”), (3) the Registration Statement on Form S-8 (Registration No. 333-248476) filed on August 28, 2020 (the “Third 2018 Plan Registration Statement”), (4) the Registration Statement on Form S-8 (Registration No. 333-258516) filed on August 5, 2021 (the “Fourth 2018 Plan Registration Statement”), (5) Registration Statement on Form S-8 (Registration No. 333-266711) filed on August 9, 2022 (the “Fifth 2018 Plan Registration Statement”), (6) Registration Statement on Form S-8 (Registration No. 333-273836) filed on August 9, 2023 (the "Sixth 2018 Plan Registration Statement") and (7) Registration Statement on Form S-8 (Registration No. 333-281388) (the "Amended and Restated 2018 Plan Registration Statement").

The contents of the Original 2018 Plan Registration Statement, the Second 2018 Plan Registration Statement, the Third 2018 Plan Registration Statement, the Fourth 2018 Plan Registration Statement, the Fifth 2018 Plan Registration Statement, the Sixth 2018 Plan Registration Statement and the Amended and Restated 2018 Plan Registration Statement, including any amendments thereto or filings incorporated therein, are incorporated herein by reference. Any items in the Original 2018 Plan Registration Statement, the Second 2018 Plan Registration Statement, the Third 2018 Plan Registration Statement, the Fourth 2018 Plan Registration Statement, the Fifth 2018 Plan Registration Statement, the Sixth Registration Statement and the Amended and Restated 2018 Plan Registration Statement not expressly changed by this Registration Statement shall be as set forth in the Original 2018 Plan Registration Statement, the Second 2018 Plan Registration Statement, the Third 2018 Plan Registration Statement, the Fourth 2018 Plan Registration Statement, the Fifth 2018 Plan Registration Statement, the Sixth 2018 Plan Registration and the Amended and Restated 2018 Plan Registration Statement, as applicable.

The 60,500 additional shares of Common Stock reserved for issuance under the 2018 ESPP registered pursuant to this Registration Statement are of the same class of securities as the shares of Common Stock registered for issuance under the 2018 ESPP pursuant to the following currently effective registration statements: (1) the Registration Statement on Form S-8 (Registration No. 333-226,703) filed on August 8, 2018 (the “Original 2018 ESPP Registration Statement”), (2) the Registration Statement on Form S-8 (Registration No. 333-258516) filed on August 5, 2021 (the “Amended and Restated 2018 ESPP Registration Statement”) and (3) the Registration

1


 

Statement on Form S-8 (Registration No. 333-281388) filed on August 8, 2024 (the “Second Amended and Restated 2018 ESPP”). The contents of the Original 2018 ESPP Registration Statement, the Amended and Restated 2018 ESPP Registration Statement and the Second Amended and Restated 2018 ESPP Registration Statement, including any amendments thereto or filings incorporated therein, are incorporated herein by reference. Any items in the Original 2018 ESPP Registration Statement, the Amended and Restated 2018 ESPP Registration Statement and the Second Amended and Restated 2018 ESPP Plan Registration Statement not expressly changed by this Registration Statement shall be as set forth in the Original 2018 ESPP Registration Statement, the Amended and Restated 2018 ESPP Registration Statement and the Second Amended and Restated 2018 ESPP Registration Statement, as applicable.

 

2


 

PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

The documents containing the information specified in Part I will be delivered in accordance with Form S-8 and Rule 428(b) under the Securities Act. Such documents are not required to be, and are not, filed with the Commission, either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents, and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

 

3


 

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents, which have been filed with the Commission by the Company pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as applicable, are hereby incorporated by reference in, and shall be deemed to be a part of, this Registration Statement:

the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 22, 2023 (including, for the avoidance of doubt, the information specifically incorporated by reference in the Company’s Form 10-K from the Company’s Definitive Proxy Statement for the 2025 Annual Meeting of Stockholders, filed with the Commission on April 23, 2025);
the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, filed with the Commission on May 8, 2025 and August 6, 2025, respectively;
our Current Reports on Form 8-K filed with the SEC on January 3, 2025, February 20, 2025, June 9, 2025, June 25, 2025 and August 6, 2025 (only Item 8.01); and
the description of the Company’s common stock in the Company’s Registration Statement on Form 8-A (File No. 001-35005) filed with the Commission on December 10, 2010, including any amendment or report filed by the Company for the purpose of updating such description, including Exhibit 4.2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on March 22, 2023.

All documents subsequently filed by the Company pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement that indicates that all of the shares of common stock registered hereunder have been sold or that deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the respective dates of filing of such documents, except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Item 2.02 or 7.01 or any related Item 9.01 of Form 8-K that is not deemed filed under such provisions.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein, modifies or supersedes such earlier statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

You may request a copy of these filings, at no cost, by writing or telephoning the Company at:

Two Tower Place, 7th Floor

South San Francisco, California 94080

Telephone: (833) 509-4583

Attn: Corporate Secretary

You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. The Company has not authorized anyone to provide you with different information. You should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document.

Item 4. Description of Securities.

Not applicable.

Item 5. Interests of Named Experts and Counsel.

Not applicable.

II-1


 

Item 6. Indemnification of Directors and Officers.

Not applicable.

Item 7. Exemption from Registration Claimed.

Not applicable.

Item 8. Exhibits.

See the Exhibit Index on the page immediately preceding the signatures to this Registration Statement for a list of exhibits filed as part of this Registration Statement, which Exhibit Index is incorporated herein by reference.

Item 9. Undertakings.

Not required to be filed with this Registration Statement pursuant to General Instruction E to Form S-8.

II-2


 

EXHIBIT INDEX

 

Exhibit

No.

 

Description

 

 

 

  4.1

 

Sixth Amended and Restated Certificate of Incorporation of Assembly Biosciences, Inc. (incorporated by reference to Exhibit 3.1 of the Registrant’s Annual Report on Form 10-K filed with the Commission on March 28, 2024).

 

 

 

  4.2

 

Certificate of Amendment to Sixth Amended and Restated Certificate of Incorporation of Assembly Biosciences, Inc., dated February 9, 2024 (incorporated by reference to Exhibit 3.1 to the Registrant's Current report on Form 8-K filed on February 13, 2024).

 

 

 

  4.3

 

Amended and Restated Bylaws of Assembly Biosciences, Inc., as amended on December 12, 2024 (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed with the Commission on December 13, 2024).

 

 

 

  4.4

 

Specimen Common Stock Certificate of Assembly Biosciences, Inc. (incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on 10-K filed with the Commission on March 20, 2025).

 

 

 

  5.1

 

Opinion of Skadden, Arps, Slate, Meagher & Flom LLP.

 

 

 

23.1

 

Consent of Skadden, Arps, Slate, Meagher & Flom LLP (included in Exhibit 5.1).

 

 

 

23.2

 

Consent of Independent Registered Public Accounting Firm.

 

 

 

24.1

 

Power of Attorney (included on the signature page of this Registration Statement).

 

 

 

99.1

 

Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the Commission on June 3, 2024).

 

 

 

99.2

 

Amendment No. 1 to Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the Commission on June 9, 2025).

 

 

 

99.3

 

Amendment No. 2 to Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K filed with the Commission on June 9, 2025).

 

 

 

99.4

 

Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.2 of the Registrant's Current Report on Form 8-K filed with the Commission on June 3, 2024).

 

 

 

99.5

 

Amendment No. 1 to Assembly Biosciences, Inc. Second Amended and Restated 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 of the Registrant’s Current Report on Form 8-K filed with the Commission on June 9, 2025).

 

 

 

 107

 

Filing Fees.

 

II-3


 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on August 6, 2025.

 

Assembly Biosciences, Inc.

By:

/s/ Jason A. Okazaki

Jason A. Okazaki

Chief Executive Officer and President

 

II-4


 

POWER OF ATTORNEY

We, the undersigned officers and directors of Assembly Biosciences, Inc., hereby severally constitute and appoint Jason A. Okazaki and John O. Gunderson, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him/her and in his/her name, place and stead, and in any and all capacities, to sign for us and in our names in the capacities indicated below any and all amendments (including post-effective amendments) to this registration statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he/she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his/her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons on August 6, 2025 in the capacities indicated.

 

Signature

Title

/s/ Jason A. Okazaki

Director, Chief Executive Officer and President

(Principal Executive Officer)

Jason A. Okazaki

/s/ Jeanette M. Bjorkquist

 

Vice President, Finance

(Principal Financial Officer and Principal Accounting Officer)

Jeanette M. Bjorkquist

 

/s/ William R. Ringo, Jr.

Chairman of the Board

William R. Ringo, Jr.

 

 

 

/s/ Anthony E. Altig

Director

Anthony E. Altig

/s/ Tomas Cihlar, Ph.D.

 

Director

Thomas Cihlar, Ph.D.

 

 

 

 

 

/s/ Gina Consylman

Director

Gina Consylman

 

 

 

/s/ Robert D. Cook II

 

Director

Robert D. Cook II

 

 

 

 

 

/s/ Michael Houghton, Ph.D.

Director

Michael Houghton, Ph.D.

 

 

 

/s/ Lisa R. Johnson-Pratt, M.D.

Director

Lisa R. Johnson-Pratt, M.D.

 

 

 

/s/ Susan Mahony, Ph.D.

Director

Susan Mahony, Ph.D.

 

/s/ John G. McHutchison, A.O., M.D.

Director

John G. McHutchison, A.O., M.D.

 

 

 

 

II-5


FAQ

How many Interface (TILE) shares are covered by this Form 144?

The notice covers 79,497 common shares.

What is the estimated market value of the proposed TILE share sale?

The filing lists an aggregate value of about $2.04 million.

When can the TILE shares be sold under this Form 144?

Sales may begin on or after 6 August 2025, subject to Rule 144 requirements.

What percentage of Interface’s shares outstanding does the sale represent?

Approximately 0.14 % of the 58.36 million shares outstanding.

Have there been any sales by this insider in the past three months?

No; the filing states "Nothing to Report" for prior 3-month sales.
Assembly Bioscie

NASDAQ:ASMB

ASMB Rankings

ASMB Latest News

ASMB Latest SEC Filings

ASMB Stock Data

144.04M
4.64M
39.25%
12.97%
0.4%
Biotechnology
Pharmaceutical Preparations
United States
SOUTH SAN FRANCISCO